about
Neoantigen-based cancer immunotherapyRegulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingDNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously.T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.Multifunctional nanoparticles for cancer immunotherapy.Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Targeting neoantigens to augment antitumour immunity.Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC.Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.T cell receptor β-chain repertoire analysis reveals the association between neoantigens and tumour-infiltrating lymphocytes in multifocal papillary thyroid carcinoma.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.CD8 + T-cell responses in vaccination: reconsidering targets and function in the context of chronic antigen stimulation.Towards a better cancer precision medicine: systems biology meets immunotherapy.Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion.Mechanisms of immune evasion in breast cancer.Genomics of adult and pediatric solid tumorsDissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants
P2860
Q26738693-ECCB3038-BA72-4414-BF0D-EBD6689A9788Q26742012-55EA6519-7B13-48D6-ABB1-8251B11137A0Q33627712-44C5210A-602D-4585-91DA-FACEFBB19A59Q33632100-B8D7BCD0-C741-4F60-B70E-49837AA64A90Q36021163-C75ADEA4-D068-4944-8965-0BC99DE53ECAQ37286552-D23D38FB-43D7-4968-B6FC-7C181F3627FEQ37587362-108A7346-9728-4D84-9853-4CE3A048D38EQ38744042-E071CB9C-70A1-492E-8742-E5F865C3F516Q38945576-AEA63629-C751-45B7-854D-4FD9A9548C60Q39057617-13CC3307-7F94-437A-B515-6E17D2B6BCABQ39149196-B0CF0E28-21AA-45DB-9A9E-D76EFD965E42Q39256918-5399F339-B294-4FB8-A37A-07041BE78D15Q40448711-7F28A65D-743A-4ACA-B443-E687933C3B8DQ40788906-3259F7D6-A096-4B1C-82E8-05525B6FEF5BQ45875006-6599499A-F807-49D6-9158-85372FC1A98CQ45941281-5F2FA425-FD93-431F-BA79-EC1796BD1C4BQ46406409-A02E8B96-3AF4-4EFB-9157-3F8EB34D9C65Q48231859-ECA6D431-C9B7-4A1E-BBDF-650EBDD5C6A9Q48247566-AE287303-18B6-46CA-BDEF-3D0B684DFD76Q49315568-B21B64DB-5213-4D18-86C8-4FA79D2CAD22Q49404911-4C7EDE0F-0B4C-42F3-8D6A-894524B048DBQ50130464-7DD15546-9C03-4A78-9DA0-CC2DFD9132AAQ52657150-E7DA030C-6762-46AC-8C4B-B68A34D33283Q54209283-726CF6EF-D37D-4227-8D9F-0E0B159D737BQ54967177-11C76B09-DDE7-40E8-8432-7D400531CB9DQ55118347-DF83776A-E58F-46C9-A2C7-E26AB4802F5FQ55312964-DD6699B6-15AE-46FE-A64A-575F77C7CF73Q55347716-2877F3B3-5FA3-4101-95A0-CE2FDB938FDEQ58804574-79C5076E-7FBD-4AC6-A68B-CD98FB8DC5CCQ59132141-BC3AE60F-4494-4E23-89C4-048A67FDE3AA
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cancer immunotherapy targeting neoantigens.
@en
type
label
Cancer immunotherapy targeting neoantigens.
@en
prefLabel
Cancer immunotherapy targeting neoantigens.
@en
P2860
P1476
Cancer immunotherapy targeting neoantigens.
@en
P2093
Paul F Robbins
P2860
P356
10.1016/J.SMIM.2015.11.002
P50
P577
2015-11-30T00:00:00Z